GlassScriptPhysician profile
Rachael Maina
NPI 1225587264
$2,787.11
in general payments reported to CMS, 2019-2025
21 companies · $651 in 2025
The $651 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $339 · 2023: $863 · 2024: $494 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.55 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $475.18 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $439.71 | 2021-2025 | |
| Exact Sciences Corporation | $165.96 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $165.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $162.32 | 2021 | |
| Vanda Pharmaceuticals INC. | $148.80 | 2022-2023 | Hetlioz |
| Lilly USA, LLC | $97.31 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Indivior INC. | $81.12 | 2023-2024 | Sublocade |
| Biohaven Pharmaceutical Holding Company LTD. | $75.08 | 2022 | |
| Amgen INC. | $73.66 | 2021-2024 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $67.81 | 2023-2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $36.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $32.70 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $25.91 | 2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $25.01 | 2021 | |
| Sumitomo Pharma America, INC. | $18.22 | 2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $14.66 | 2025 | Contrave |
| Bardy Diagnostics, INC. | $14.51 | 2021 | |
| Sanofi Pasteur INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Maina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.